Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B R Davies

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The Journal of Urology|June 11, 2005
Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancerS J Dovedi, J A Kirby, H Atkins, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|November 18, 2015
Bespoke video vignettes - an approach to enhancing reflective learning developed by dental undergraduates and their clinical teachersB R Davies, A N Leung, S M Dunne, et al.
Oncogene|October 11, 2001
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancerI A Steele, R J Edmondson, J N Bulmer, et al.
Histopathology|October 27, 2004
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasmsP Mehrotra, A Okpokam, R Bouhaidar, et al.
Biochemical Society Symposium|March 26, 1998
Use of DNA transfer in the induction of metastasis in experimental mammary systemsR Barraclough, H J Chen, B R Davies, et al.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1992
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rateB Leyland-Jones, B R Davies, K Clagett-Carr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-populationN C Turner, E Alarcón, A C Armstrong, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Journal of Urology|June 11, 2005
Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancerS J Dovedi, J A Kirby, H Atkins, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|November 18, 2015
Bespoke video vignettes - an approach to enhancing reflective learning developed by dental undergraduates and their clinical teachersB R Davies, A N Leung, S M Dunne, et al.
Oncogene|October 11, 2001
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancerI A Steele, R J Edmondson, J N Bulmer, et al.
Histopathology|October 27, 2004
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasmsP Mehrotra, A Okpokam, R Bouhaidar, et al.
Biochemical Society Symposium|March 26, 1998
Use of DNA transfer in the induction of metastasis in experimental mammary systemsR Barraclough, H J Chen, B R Davies, et al.
British Journal of Cancer|February 21, 2012
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsS V Holt, A Logié, R Odedra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1992
Patient treatment on a compassionate basis: documentation of high adverse drug reaction rateB Leyland-Jones, B R Davies, K Clagett-Carr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2019
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-populationN C Turner, E Alarcón, A C Armstrong, et al.
Pageof 4